Cargando…

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormali...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Nikhil, Khunger, Arjun, Vachhani, Pankit, Colvin, Teresa A., Hattoum, Alexander, Spangenthal, Edward, Curtis, Anne B., Dy, Grace K., Ernstoff, Marc S., Puzanov, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465686/
https://www.ncbi.nlm.nih.gov/pubmed/31011325
http://dx.doi.org/10.1159/000498985
Descripción
Sumario:The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy. We present a series of five cases of ICI-related cardio-toxicity diagnosed and managed at Roswell Park Comprehensive Cancer Center along with a review of published case reports in the literature. Our series highlights the importance of high clinical suspicion, early diagnosis of myocarditis, and prompt initiation of immunosuppressive therapy.